{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:45:48Z","timestamp":1792817148404,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00601-w","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:02:09Z","timestamp":1696525329000},"page":"1459-1477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting DORIS Remission and LLDAS in SLE: A Review"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-0447","authenticated-orcid":false,"given":"Agner R.","family":"Parra S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangi","family":"Kandane-Rathnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sorrentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"601_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","volume":"48","author":"SA Chambers","year":"2009","unstructured":"Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48:673\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.651249","volume":"8","author":"A Gomez","year":"2021","unstructured":"Gomez A, Qiu V, Cederlund A, et al. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med. 2021;8: 651249.","journal-title":"Front Med"},{"key":"601_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi S, Ji J, Song G. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727\u201334.","journal-title":"Lupus"},{"key":"601_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-015-0702-6","volume":"17","author":"J Mikdashi","year":"2015","unstructured":"Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.","journal-title":"Arthritis Res Ther"},{"key":"601_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345.","journal-title":"Ann Rheum Dis"},{"key":"601_CR6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","volume":"18","author":"AR Parra Sanchez","year":"2022","unstructured":"Parra Sanchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18:146\u201357.","journal-title":"Nat Rev Rheumatol"},{"key":"601_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8: e000538.","journal-title":"Lupus Sci Med"},{"key":"601_CR8","doi-asserted-by":"publisher","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","volume":"59","author":"V Golder","year":"2020","unstructured":"Golder V, Tsang-A-Sjoe M. Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford). 2020;59:v19\u201328.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR9","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/jcm11133587","volume":"11","author":"M Gerosa","year":"2022","unstructured":"Gerosa M, Beretta L, Ramirez GA, et al. Long-term clinical outcome in systemic lupus erythematosus patients followed for more than 20 years: the Milan Systemic Lupus Erythematosus Consortium (SMiLE) cohort. J Clin Med. 2022;11:3587.","journal-title":"J Clin Med"},{"key":"601_CR10","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1093\/rheumatology\/keaa120","volume":"59","author":"D Gao","year":"2020","unstructured":"Gao D, Hao Y, Mu L, et al. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naive patients with systemic lupus erythematosus. Rheumatology (Oxford). 2020;59:3400\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR11","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.40571","volume":"70","author":"M Petri","year":"2018","unstructured":"Petri M, Magder LS. Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheum. 2018;70:1790\u20135.","journal-title":"Arthritis Rheum"},{"key":"601_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000234","volume":"5","author":"C Tani","year":"2018","unstructured":"Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018;5: e000234.","journal-title":"Lupus Sci Med"},{"key":"601_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000553","volume":"9","author":"Y Hao","year":"2022","unstructured":"Hao Y, Ji L, Gao D, et al. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study. Lupus Sci Med. 2022;9: e000553.","journal-title":"Lupus Sci Med"},{"key":"601_CR14","doi-asserted-by":"publisher","first-page":"E103","DOI":"10.1016\/S2665-9913(19)30048-7","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatol. 2019;1:E103\u201310.","journal-title":"Lancet Rheumatol"},{"key":"601_CR15","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"601_CR16","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1:e95\u2013102.","journal-title":"Lancet Rheumatol"},{"key":"601_CR17","doi-asserted-by":"publisher","unstructured":"Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2023. https:\/\/doi.org\/10.1136\/ard-2022-222748. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36690388.","DOI":"10.1136\/ard-2022-222748"},{"key":"601_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","volume":"78","author":"S Oon","year":"2019","unstructured":"Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78:629\u201333.","journal-title":"Ann Rheum Dis"},{"key":"601_CR19","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/1756-185X.13663","volume":"22","author":"GA Ramirez","year":"2019","unstructured":"Ramirez GA, Canti V, Moiola L, et al. Performance of SLE responder index and lupus low disease activity state in real life: a prospective cohort study. Int J Rheum Dis. 2019;22:1752\u201361.","journal-title":"Int J Rheum Dis"},{"key":"601_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000616","volume":"9","author":"MF Ugarte-Gil","year":"2022","unstructured":"Ugarte-Gil MF, Gamboa-Cardenas RV, Re\u00e1tegui-Sokolova C, et al. LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Lupus Sci Med. 2022;9: e000616.","journal-title":"Lupus Sci Med"},{"key":"601_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","volume":"24","author":"R Kandane-Rathnayake","year":"2022","unstructured":"Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al. \u2018Not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022;24:70.","journal-title":"Arthritis Res Ther"},{"key":"601_CR22","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","volume":"4","author":"R Kandane-Rathnayake","year":"2022","unstructured":"Kandane-Rathnayake R, Golder V, Louthrenoo W, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4:e822\u201330.","journal-title":"Lancet Rheumatol"},{"key":"601_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/acr.23867","volume":"72","author":"C Sharma","year":"2020","unstructured":"Sharma C, Raymond W, Eilertsen G, Nossent J. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72:447\u201351.","journal-title":"Arthritis Care Res"},{"key":"601_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332\u201340.","journal-title":"Ann Rheum Dis"},{"key":"601_CR25","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319.","journal-title":"Lancet Rheumatol"},{"key":"601_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/annrheumdis-2017-212504","volume":"77","author":"EF Morand","year":"2018","unstructured":"Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018;77:706\u201313.","journal-title":"Ann Rheum Dis"},{"key":"601_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheum. 2023;75:253\u201365.","journal-title":"Arthritis Rheum"},{"key":"601_CR28","doi-asserted-by":"crossref","unstructured":"Morand EF, van Vollenhoven R, Furie R, et al. OP0051 Lupus Low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab. In: Oral presentation at: European Congress of Rheumatology (EULAR); 2023; Milan, Italy, 31 May\u20133 June 2023.","DOI":"10.1136\/annrheumdis-2023-eular.1568"},{"key":"601_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2022","unstructured":"Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2022;75:242\u201352.","journal-title":"Arthritis Rheum"},{"key":"601_CR30","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1093\/rheumatology\/keaa029","volume":"59","author":"EF Morand","year":"2020","unstructured":"Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59:2930\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR31","unstructured":"Aranow C, Allaart C, Amoura Z, et al. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: the phase 3, randomized, placebo-controlled BLISS-BELIEVE study. ACR convergence 2021; 2021; Virtual, 5\u20139 November."},{"key":"601_CR32","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401:1001\u201310.","journal-title":"Lancet"},{"key":"601_CR33","unstructured":"van Vollenhoven R, Morand E, Furie R, et al. Attainment of remission with anifrolumab: a post hoc analysis of pooled TULIP-1 and TULIP-2 datasets. ACR Convergence 2022; 2022; Philadelphia, PA, 10\u201314 November."},{"key":"601_CR34","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124\u201332.","journal-title":"Nat Med"},{"key":"601_CR35","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1093\/rheumatology\/keac185","volume":"61","author":"S Emamikia","year":"2022","unstructured":"Emamikia S, Oon S, Gomez A, et al. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61:4752\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13075-017-1256-6","volume":"19","author":"V Golder","year":"2017","unstructured":"Golder V, Kandane-Rathnayake R, Hoi AY, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19:62.","journal-title":"Arthritis Res Ther"},{"key":"601_CR37","unstructured":"Golder V, Kandane-Rathnayake R, Li N, et al. Association of sustained Lupus Low Disease Activity State with improved outcomes in SLE: a multinational prospective cohort study. ACR Convergence 2022; 2022; Philadelphia, PA, 10\u201314 November."},{"key":"601_CR38","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/acr.24023","volume":"72","author":"AL Yeo","year":"2020","unstructured":"Yeo AL, Koelmeyer R, Kandane-Rathnayake R, et al. Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72:1289\u201395.","journal-title":"Arthritis Care Res"},{"key":"601_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721\u201331.","journal-title":"Lancet"},{"key":"601_CR40","unstructured":"ClinicalTrials.gov. A single arm 24 weeks pilot study of belimumab in treatment of early systemic lupus erythematosus. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04956484?term=belimumab&draw=2&rank=2. Accessed 22 Sept 2022."},{"key":"601_CR41","unstructured":"ClinicalTrials.gov. Pilot trial of belimumab in early lupus. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03543839?term=belimumab&draw=3&rank=22. Accessed 22 Sept 2022."},{"key":"601_CR42","unstructured":"ClinicalTrials.gov. A study to evaluate effectiveness and safety of deucravacitinib (BMS-986165) compared with placebo in participants with active systemic lupus erythematosus (POETYK SLE-2). 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05620407?term=nct05620407&draw=2&rank=1. Accessed 15 Feb 2023."},{"key":"601_CR43","unstructured":"ClinicalTrials.gov. Optimization of glucocorticoid taper strategies for SLE-ITP. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05506033?term=NCT05506033&draw=2&rank=1. Accessed 26 Sept 2022."},{"key":"601_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102398","volume":"110","author":"M Dougados","year":"2020","unstructured":"Dougados M. Treat to target in axial spondyloarthritis: from its concept to its implementation. J Autoimmun. 2020;110: 102398.","journal-title":"J Autoimmun"},{"key":"601_CR45","doi-asserted-by":"publisher","first-page":"adv00402","DOI":"10.2340\/00015555-3751","volume":"101","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Dermato-Venereol. 2021;101:adv00402.","journal-title":"Acta Dermato-Venereol."},{"key":"601_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263\u20139.","journal-title":"Lancet"},{"key":"601_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/rheumatology\/keac242","volume":"62","author":"G Durao-Carvalho","year":"2023","unstructured":"Durao-Carvalho G, Fernandez-Gonzalez R, Goulden B, Farinha F, Isenberg D. Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period. Rheumatology (Oxford). 2023;62:209\u201316.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR48","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/rheumatology\/keac462","volume":"62","author":"I Altabas-Gonzalez","year":"2023","unstructured":"Altabas-Gonzalez I, Rua-Figueroa I, Rubino F, et al. Does expert opinion match the definition of Lupus Low Disease Activity State? prospective analysis of 500 patients from a Spanish multicentre cohort. Rheumatology (Oxford). 2023;62:1162\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR49","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1093\/rheumatology\/keac002","volume":"61","author":"J Kikuchi","year":"2022","unstructured":"Kikuchi J, Hanaoka H, Saito S, et al. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford). 2022;61:3777\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000516","volume":"8","author":"J Mucke","year":"2021","unstructured":"Mucke J, Kuss O, Brinks R, Schanze S, Schneider M. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial. Lupus Sci Med. 2021;8: e000516.","journal-title":"Lupus Sci Med"},{"key":"601_CR51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.autrev.2010.08.016","volume":"10","author":"PP Smith","year":"2010","unstructured":"Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010;10:43\u20135.","journal-title":"Autoimmun Rev"},{"key":"601_CR52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","volume":"76","author":"M Zen","year":"2017","unstructured":"Zen M, Iaccarino L, Gatto M, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann Rheum Dis. 2017;76:562\u20135.","journal-title":"Ann Rheum Dis"},{"key":"601_CR53","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3899\/jrheum.171307","volume":"45","author":"SO Keeling","year":"2018","unstructured":"Keeling SO, Bissonauth A, Bernatsky S, et al. Practice variations in the diagnosis, monitoring, and treatment of systemic lupus erythematosus in Canada. J Rheumatol. 2018;45:1440\u20137.","journal-title":"J Rheumatol"},{"key":"601_CR54","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/rheumatology\/key103","volume":"57","author":"Z Touma","year":"2018","unstructured":"Touma Z, Gladman DD, Su J, Anderson N, Urowitz MB. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford). 2018;57:1370\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR55","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/annrheumdis-2022-eular.3044","volume":"81","author":"I Altab\u00e1s Gonz\u00e1lez","year":"2022","unstructured":"Altab\u00e1s Gonz\u00e1lez I, Rua-Figueroa I, Jim\u00e9nez N, et al. POS0759 Does LLDAS definition match the rheumatologist opinion? The first visit evaluation of a longitudinal Spanish multicenter study to assess reasons of disagreement. Ann Rheum Dis. 2022;81:665\u20136 (abstract).","journal-title":"Ann Rheum Dis"},{"key":"601_CR56","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.semarthrit.2017.01.007","volume":"46","author":"V Golder","year":"2017","unstructured":"Golder V, Huq M, Franklyn K, et al. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Semin Arthritis Rheum. 2017;46:798\u2013803.","journal-title":"Semin Arthritis Rheum"},{"key":"601_CR57","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/rheumatology\/keab005","volume":"60","author":"J Mucke","year":"2021","unstructured":"Mucke J, D\u00fcsing C, Klose N, Schneider M, Chehab G. Remission in SLE-do DORIS criteria match the treating physician\u2019s judgment? A cross-sectional study to assess reasons for discordance. Rheumatology (Oxford). 2021;60:4298\u2013305.","journal-title":"Rheumatology (Oxford)"},{"key":"601_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum. 2017;69:376\u201386.","journal-title":"Arthritis Rheum"},{"key":"601_CR59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211\u201321.","journal-title":"N Engl J Med"},{"key":"601_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222\u201331.","journal-title":"Lancet"},{"key":"601_CR61","unstructured":"ClinicalTrials.gov. A study of baricitinib in participants with systemic lupus erythematosus (SLE) (SLE-BRAVE-X). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03843125. Accessed June 2022."},{"key":"601_CR62","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918\u201330.","journal-title":"Arthritis Rheum"}],"updated-by":[{"DOI":"10.1007\/s40744-024-00679-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00601-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00601-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:01:50Z","timestamp":1717830110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00601-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00601-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40744-024-00679-w","asserted-by":"object"}]},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40744-024-00679-w","URL":"https:\/\/doi.org\/10.1007\/s40744-024-00679-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Agner R. Parra S\u00e1nchez has received grant\/research support (institutional grants) from AstraZeneca; received support for attending meetings and\/or travel from Amsterdam UMC. The work of ARPS is supported by the European Union\u2019s Horizon 2020 research and innovation program (\u201cARCAID\u201d; ; grant agreement nr. 847551). Ronald F. van Vollenhoven has received grant\/research support from Bristol Myers Squibb (BMS) and UCB; received support for educational programs from AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB; received consulting fees from AbbVie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Pfizer, and UCB; and received speaking fees and\/or honoraria from AbbVie, AstraZeneca, BMS, Galapagos, GlaxoSmithKline (GSK), Janssen, Pfizer, and UCB. Eric F. Morand has received grant support from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly and Company, EMD Serono, Genentech, GSK, Janssen, and UCB Pharma; received consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Eli Lilly and Company, EMD Serono, Genentech, GSK, Janssen, Novartis, Servier, Wolf, and Zenas; received speaking fees and\/or honoraria from AstraZeneca, Biogen, BMS, EMD Serono, and Gilead; received support for attending meetings and\/or travel from AstraZeneca; and served in a leadership or fiduciary role as Board Director at Rare Voices Australia. Ian N. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre (NIHR 203308). His institution has received research grants from GSK and Genzyme\/Sanofi and consultancy fees from GSK, UCB, Eli Lilly, BMS, Merck Serono, Aurinia and IL-TOO. Dr Bruce has received speaker fees from GSK, AstraZeneca and UCB; he also participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca and Merck Serono. Rangi Kandane-Rathnayake declares that there is no conflict of interest. Gudrun Weiss, Raj Tummala, and Hussein Al-Mossawi are all employees of and may hold stock in AstraZeneca. Alessandro Sorrentino is an employee of AstraZeneca and holds stock in Abbott, Galapagos, Gilead, and Moderna.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}